Answer
Patients who develop dizziness, confusion, somnolence or fatigue during Pegasys (peginterferon alfa-2a) treatment should avoid driving or operating machinery.
Sources for this answer
- Pegasys 90 micrograms, 135 micrograms and 180 micrograms solution for injection in pre-filled syringepharmaand GmbH · emc · SmPC §4.7 Effects on ability to drive and use machines · Version 2Document updated
Sources checked